Format
Sort by
Items per page

Send to

Choose Destination

Best matches for malignant neoplasm of prostate AND prostate cancer screening AND prostate cancer screening; prostate specific antigen test (psa):

Search results

Items: 1 to 20 of 1881

1.

PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.

Kearns JT, Holt SK, Wright JL, Lin DW, Lange PH, Gore JL.

Cancer. 2018 Jul 1;124(13):2733-2739. doi: 10.1002/cncr.31337. Epub 2018 May 21.

PMID:
29781117
2.

Role of Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy and Transrectal Ultrasound in Evaluation of Prostatic Pathologies with Focus on Prostate Cancer.

Lahoti AM, Dhok AP, Rantnaparkhi CR, Rawat JS, Chandak NU, Tawari HS.

Pol J Radiol. 2017 Dec 15;82:827-836. doi: 10.12659/PJR.903958. eCollection 2017.

3.
4.

Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial.

Martin RM, Donovan JL, Turner EL, Metcalfe C, Young GJ, Walsh EI, Lane JA, Noble S, Oliver SE, Evans S, Sterne JAC, Holding P, Ben-Shlomo Y, Brindle P, Williams NJ, Hill EM, Ng SY, Toole J, Tazewell MK, Hughes LJ, Davies CF, Thorn JC, Down E, Davey Smith G, Neal DE, Hamdy FC; CAP Trial Group.

JAMA. 2018 Mar 6;319(9):883-895. doi: 10.1001/jama.2018.0154.

PMID:
29509864
5.

A Panel of Biomarkers for Diagnosis of Prostate Cancer Using Urine Samples.

Guo J, Yang J, Zhang X, Feng X, Zhang H, Chen L, Johnson H, Persson JL, Xiao K.

Anticancer Res. 2018 Mar;38(3):1471-1477.

PMID:
29491074
6.

Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts.

Seibert TM, Fan CC, Wang Y, Zuber V, Karunamuni R, Parsons JK, Eeles RA, Easton DF, Kote-Jarai Z, Al Olama AA, Garcia SB, Muir K, Grönberg H, Wiklund F, Aly M, Schleutker J, Sipeky C, Tammela TL, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah P, Pashayan N, Khaw KT, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Wokolorczyk D, Kluzniak W, Cannon-Albright L, Brenner H, Cuk K, Saum KU, Park JY, Sellers TA, Slavov C, Kaneva R, Mitev V, Batra J, Clements JA, Spurdle A, Teixeira MR, Paulo P, Maia S, Pandha H, Michael A, Kierzek A, Karow DS, Mills IG, Andreassen OA, Dale AM; PRACTICAL Consortium*.

BMJ. 2018 Jan 10;360:j5757. doi: 10.1136/bmj.j5757.

7.

Impact of numeracy on understanding of prostate cancer risk reduction in PSA screening.

Koo K, Brackett CD, Eisenberg EH, Kieffer KA, Hyams ES.

PLoS One. 2017 Dec 28;12(12):e0190357. doi: 10.1371/journal.pone.0190357. eCollection 2017.

8.

68Ga PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer.

Iravani A, Hofman MS, Mulcahy T, Williams S, Murphy D, Parameswaran BK, Hicks RJ.

Cancer Imaging. 2017 Dec 21;17(1):31. doi: 10.1186/s40644-017-0133-5.

9.

Tumor marker α-fetoprotein receptor does not discriminate between benign prostatic disease and prostate cancer.

Smrkolj T, Gubina B, Bizjak J, Kumer K, Fabjan T, Osredkar J.

Adv Clin Exp Med. 2017 Oct;26(7):1085-1090. doi: 10.17219/acem/65432.

10.

Characterizing indeterminate (Likert-score 3/5) peripheral zone prostate lesions with PSA density, PI-RADS scoring and qualitative descriptors on multiparametric MRI.

Brizmohun Appayya M, Sidhu HS, Dikaios N, Johnston EW, Simmons LA, Freeman A, Kirkham AP, Ahmed HU, Punwani S.

Br J Radiol. 2018 Feb;91(1083):20170645. doi: 10.1259/bjr.20170645. Epub 2017 Dec 15.

PMID:
29189042
11.

Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States.

Kelly SP, Anderson WF, Rosenberg PS, Cook MB.

Eur Urol Focus. 2018 Jan;4(1):121-127. doi: 10.1016/j.euf.2017.10.014. Epub 2017 Nov 20.

PMID:
29162421
13.

What Are We Missing? False-Negative Cancers at Multiparametric MR Imaging of the Prostate.

Borofsky S, George AK, Gaur S, Bernardo M, Greer MD, Mertan FV, Taffel M, Moreno V, Merino MJ, Wood BJ, Pinto PA, Choyke PL, Turkbey B.

Radiology. 2018 Jan;286(1):186-195. doi: 10.1148/radiol.2017152877. Epub 2017 Oct 20.

PMID:
29053402
14.

Barriers and facilitators to healthy lifestyle and acceptability of a dietary and physical activity intervention among African Caribbean prostate cancer survivors in the UK: a qualitative study.

Er V, Lane JA, Martin RM, Persad R, Chinegwundoh F, Njoku V, Sutton E.

BMJ Open. 2017 Oct 15;7(10):e017217. doi: 10.1136/bmjopen-2017-017217.

15.

[Rates of total and free PSA prescriptions in France (2012-2014)].

Tuppin P, Leboucher C, Peyre-Lanquar G, Lamy PJ, Gabach P, Rébillard X.

Presse Med. 2017 Oct;46(10):e237-e247. doi: 10.1016/j.lpm.2017.04.015. Epub 2017 Oct 12. French.

PMID:
29031682
16.
17.

Prostate cancer screening: Knowledge, attitudes and practices in a sample of men in Italy. A survey.

Morlando M, Pelullo CP, Di Giuseppe G.

PLoS One. 2017 Oct 12;12(10):e0186332. doi: 10.1371/journal.pone.0186332. eCollection 2017.

18.

Analysis of histological findings obtained combining US/mp-MRI fusion-guided biopsies with systematic US biopsies: mp-MRI role in prostate cancer detection and false negative.

Faiella E, Santucci D, Greco F, Frauenfelder G, Giacobbe V, Muto G, Zobel BB, Grasso RF.

Radiol Med. 2018 Feb;123(2):143-152. doi: 10.1007/s11547-017-0814-y. Epub 2017 Oct 10.

PMID:
29019021
19.

Effects of increasing the PSA cutoff to perform additional biomarker tests before prostate biopsy.

Nordström T, Adolfsson J, Grönberg H, Eklund M.

BMC Urol. 2017 Oct 3;17(1):92. doi: 10.1186/s12894-017-0281-8.

20.

The eternal enigma in prostatic biopsy access route.

Fabiani A, Principi E, Filosa A, Servi L.

Arch Ital Urol Androl. 2017 Oct 3;89(3):245-246. doi: 10.4081/aiua.2017.3.245.

Supplemental Content

Loading ...
Support Center